Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Tirzepatide (Mounjaro/Zepbound) is a dual GLP-1 and GIP receptor agonist it activates two separate hormonal pathways simultaneously
Retatrutide leads on published weight loss data (28.3% vs ~19% survodutide and 20.9% tirzepatide), receptor coverage (triple agonist vs dual), and liver fat reduction (82%)
Hypoglycaemia: Uncommon in patients without diabetes
[1] According to the Summary of Product Characteristics (SmPC) approved by the Medicines and Healthcare products Regulatory Agency (MHRA), gastrointestinal disturbances affect a substantial proportion of patients initiating Ozempic therapy
Bharucha AE, Camilleri M, Veil E, Burton D, Zinsmeister AR (2013) Comprehensive assessment of gastric emptying with a stable isotope breath test
doi: Taylor-Barnes K
US$ 24.54
US$ 27.01
US$ 20.84
US$ 21.88
